Core Insights - C4 Therapeutics Inc. (NASDAQ:CCCC) is recognized as a promising biotech penny stock by analysts, with Barclays recently lowering its price target to $5 from $10 while maintaining an Overweight rating [1] - TD Cowen initiated coverage with a Buy rating, emphasizing the company's unique position in achieving clinical validation for both molecular glues and heterobifunctional degraders, particularly highlighting cemsigwat/Cemsi's potential in treating multiple myeloma [2] Company Developments - In Q3 2025, C4 Therapeutics' lead candidate, cemsidomide, demonstrated a 53% overall response rate at the highest dose level of 100 µg in Phase 1 trials for multiple myeloma, showcasing a differentiated safety profile in heavily pre-treated patients [3] - The company plans to launch the Phase 2 MOMENTUM trial in combination with dexamethasone in Q1 2026, with potential for accelerated approval, followed by a Phase 1b trial with Pfizer's elranatamab in Q2 2026 [4] - C4 Therapeutics is also utilizing its TORPEDO platform to advance a discovery pipeline targeting non-oncology indications, indicating a broader strategic focus beyond oncology [4]

Core Insights - C4 Therapeutics, Inc. is participating in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, indicating its active engagement in the healthcare investment community [1][2] - The company focuses on advancing targeted protein degradation science to develop innovative medicines aimed at transforming patient outcomes [3] Company Overview - C4 Therapeutics is a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker CCCC [3] - The company is dedicated to creating a new generation of medicines through targeted protein degradation, which aims to address difficult-to-treat diseases [3] - C4T utilizes its TORPEDO platform to design and optimize small-molecule medicines, enhancing the potential to overcome drug resistance and improve patient outcomes [3] Event Details - The fireside chat will take place on December 3, 2025, at 3:25 pm ET, with a live webcast available on the company's website [2] - An archived replay of the webcast will be accessible for approximately 90 days following the live event [2]